UroToday

FDA Approves Smart Programmer for the InterStim™ System

San Francisco, CA USA (UroToday.com) -- Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence. Medtronic plc announced U.S. Food and Drug ...
BioSpace

Medtronic, Inc. Receives FDA Approval For InterStim(R) II System For Treatment Of Overactive Bladder, Urinary Retention

MINNEAPOLIS--(BUSINESS WIRE)--July 5, 2006--Medtronic, Inc. (NYSE:MDT - News), today announced that the U.S. Food and Drug Administration (FDA) has approved the company's InterStim® II system for the ...
MD&M East

Medtronic Scores FDA Nod for Next-Gen InterStim

Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...
MassDevice

FDA approves Medtronic’s next-gen InterStim X system

Medtronic (NYSE:MDT) announced today that the FDA approved its next-generation InterStim X recharge-free device. The medtech giant has made the latest sacral neuromodulation (SNM) therapy product from ...
BioSpace

FDA Approves Smart Programmer for the InterStim System

“In addition to simplified programming and ongoing management of InterStim therapy, the smart programmer is discreet, which is meaningful to patients because OAB can greatly impact confidence, ...